GlassScriptPhysician profile
Steven L Pugh
NPI 1952394272
$161,960.25
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84K · 2020: $38K · 2021: $13K · 2022: $27K · 2023: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $39,863.74 | 2019-2023 | Vumerity |
| Emd Serono, INC. | $35,020.73 | 2019-2023 | Mavenclad |
| Genzyme Corporation | $25,799.75 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $23,700.40 | 2020-2022 | |
| Genentech USA, INC. | $16,838.83 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $9,178.18 | 2019-2022 | |
| Celgene Corporation | $7,690.06 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,028.65 | 2019-2022 | |
| Abbvie INC. | $363.88 | 2021-2023 | |
| Amgen INC. | $227.06 | 2019-2022 | |
| Boston Scientific Corporation | $219.20 | 2019-2022 | |
| Acorda Therapeutics, INC | $149.84 | 2019-2022 | |
| Impel Pharmaceuticals INC. | $144.49 | 2022 | |
| Allergan, INC. | $139.81 | 2019-2022 | |
| Argenx US, INC. | $129.09 | 2022 |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Pugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.